Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 1Diagnosis: Lung CancerNCT ID: NCT01970865
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-408
Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .
Conducting Institutions: Massachusetts General Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute
Overall PI: Alice Shaw, MD, PhD,
Massachusetts General Hospital
Site-responsible Investigators: Geoffrey Oxnard, MD,
Dana Farber Cancer Institute
Contacts: Dana-Farber Cancer Institute:
Kelly Masone, 617-632-3383,
email@example.comMassachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100